Lung cancers can use two different mechanisms to evade KRAS-inhibiting #drugs

Some tumor cells develop resistance by amplifying the #KRAS gene, while others change their tumor type, #MIT researchers have found
#Cancer #Genetics #Health #Science

Lung cancers can use two different mechanisms to evade KRAS-inhibiting #drugs

Some tumor cells develop resistance by amplifying the #KRAS gene, while others change their tumor type, #MIT researchers have found
#Cancer #Genetics #Health #Science

🆕 ADVANCE ONLINE 🆕

RESEARCH PAPER: Firefox, a protein encoded by circular PVT1, is essential for MYC-driven oncogenesis
By Tiwari et al. and Anindya Bagchi
➡️ https://ow.ly/yESB50ZR92i

Also read about Honeybadger:
➡️ https://ow.ly/WsCF50ZR92k

#cancer #MYC #KRAS #lncRNA

#TherapeuticPotential of combining #IRE1α and #KRAS inhibition in #PancreaticDuctalAdenocarcinoma doi.org/10.1073/pnas... #PDAC #Hypoxia #Oncology #LiverCancer #SolidTumor #TranslationalScience

We show that combination therapies that stimulate antitumour immunity promote the immune-mediated elimination of KRAS-G12C inhibitor-resistant subpopulations, providing a potential strategy to overcome drug resistance that may have relevance in broader therapeutic settings. #KRAS #DrugResistance

In new #pancreascancer research, @muzumdarlab.bsky.social et al. find that the pre-existing molecular state of a #PDAC cell exerts greater influence over how a #KRAS mutation behaves than the identity of the mutation itself.
medicine.yale.edu/cancer/publi...
@molecularomics.bsky.social

New KRAS treatment options are changing what's possible for pancreatic cancer patients. Thanks to the Pancreatic Cancer Action Network, #SmartPatients were able to ask GI oncologist Dr. Noelle LoConte questions about these findings. Read more: https://ow.ly/r0Ym50ZKItk

#KRAS #PanCAN

🧬Can #KRAS mutations change the tumor microbiome?
A recent study found that mutant KRAS enriches Bacteroides acidifaciens, which selectively promotes KRAS-mutant colorectal cancer (#CRC) growth.
🔄KRAS → B. acidifaciens → SusF–ARHGEF2 → RAF–MEK–ERK → tumor growth

Shares in #China's #Hutchmed surged today after #GSK paid $110 million upfront for rights to a preclinical-stage #KRAS and #EGFR-targeted drug with potential in colorectal, pancreatic, and lung #cancer.

pharmaphorum.com/news/hutchme...